Trials / Not Yet Recruiting
Not Yet RecruitingNCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
(CHANT)A Prospective, Multicenter, Non-interventionistic Real-world Study of Duvelisib Capsules in the Treatment of Non-Hodgkin's Lymphoma (NHL).
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.
Detailed description
This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib administered to subjects who have been diagnosed with non-Hodgkin's lymphoma that is relapsed or refractory, including but not limited to the following subtypes : a) Follicular lymphoma(FL); b) Chronic lymphocytic leukemia/small lymphocytic lymphoma or Richter syndrome(CLL/SLL or RS); c) Marginal zone lymphoma(MZL); d) Peripheral T-cell lymphoma(PTCL); e) Diffuse large B-cell lymphoma(DLBCL).
Conditions
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Richter Syndrome
- Marginal Zone Lymphoma
- Peripheral T Cell Lymphoma
- Diffuse Large B Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duvelisib | This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients. |
Timeline
- Start date
- 2023-10-20
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
- First posted
- 2023-06-28
- Last updated
- 2023-10-23
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05923502. Inclusion in this directory is not an endorsement.